Publications by authors named "Aurelia E Reiser"
Grimm, Mirjam, Lucie Ziegler, Annina Seglias, Maamed Mademilov, Kamila Magdieva, Gulzada Mirzalieva, Aijan Taalaibekova, Simone Suter, Simon R. Schneider, Fiona Zoller, Vera Bissig, Lukas Reinhard, Meret Bauer, Julian Müller, Tanja L. Ulrich, Arcangelo F.
View Article and Find Full Text PDFArticle Synopsis
- A study was conducted to determine the effects of moderate altitude exposure on visuomotor performance in healthy adults aged 40 and older while exploring if acetazolamide could mitigate these effects.
- The trial included 59 participants, who were given either acetazolamide or a placebo before and during their time at a high altitude of 3100m, with performance assessed through a computer test measuring directional error in a cursor tracking task.
- Results showed that visuomotor performance declined at high altitude compared to lower altitudes, but acetazolamide significantly improved performance metrics, indicating it may help counteract altitude-related visuomotor impairments.
BACKGROUND: We evaluated the efficacy of acetazolamide in preventing adverse altitude effects in patients with moderate to severe chronic obstructive pulmonary disease (COPD) and in healthy lowlanders 40 years of age or older. METHODS: Trial 1 was a randomized, double-blind, parallel-design trial in which 176 patients with COPD were treated with acetazolamide capsules (375 mg/day) or placebo, starting 24 hours before staying for 2 days at 3100 m. The mean (±SD) age of participants was 57±9 years, and 34% were women.
View Article and Find Full Text PDF